

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400001

Scrip code- 531207

Subject: Integrated Filing (Financial) for the quarter and nine-months ended 31st December, 2024.

Dear Sir/ Madam,

In accordance with amendments to the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31st December, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, the Integrated Filing (Financial) for the third quarter and nine-months ended 31st December, 2024 is enclosed herewith.

FOR RAYMED LABS LIMITED

(Prashant Nathmal Bajaj)

Director

DIN: 06634046

Date: 13th February, 2025

Place: Mumbai

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

Integrated Filing (Financial) for third quarter and nine months ended 31st December, 2024

- A. Unaudited Financial Results (Standalone and Consolidated) for Q3 and 9M ended December 31, 2024
- Enclosed

- B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.: **Not Applicable**

- C. Disclosure of outstanding default on loans and debt securities: **No default as at 31st December, 2024.**

- D. Disclosure of related party transactions (applicable only for half-yearly filings i.e. 2nd and 4th quarter):
Not applicable for quarter ended 31st December, 2024.

- E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e. 4th quarter): **Not applicable for quarter ended 31st December, 2024.**

RAYMED LABS LIMITED

UNAUDITED BALANCE SHEET AS AT DECEMBER 31, 2024

(INR in Lakhs)

Particulars	As at Dec 31, 2024	As at March 31, 2024
I ASSETS		
1. Non Current Assets		
(a) Property, Plant and Equipment	14.14	14.58
(b) Capital Work-In-Progress	-	-
(c) Investment Property	-	-
(d) Intangible Assets	-	-
(e) Intangible Assets Under Development	-	-
(f) Financial Assets	-	-
(g) Income Tax Assets (Net)	-	-
(h) Other Non Current Assets	-	-
	<u>14.14</u>	<u>14.58</u>
2. Current Assets		
(a) Inventories	-	-
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Cash and Cash Equivalents	55.79	0.05
(iv) Other Bank Balances other than (iii) above	-	-
(v) Loans	0.45	0.45
(vi) Others	-	-
(c) Other Current Assets	-	-
	<u>56.24</u>	<u>0.50</u>
Total Assets	<u>70.38</u>	<u>15.08</u>
II EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	(696.43)	(668.11)
	<u>(269.08)</u>	<u>(240.76)</u>
LIABILITIES		
1. Non Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	327.13	243.17
(b) Provisions	-	-
(c) Deferred Tax Liabilities (Net)	-	-
	<u>327.13</u>	<u>243.17</u>
2. Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(iii) Other Financial Liabilities	5.00	5.00
(b) Other Current Liabilities	7.34	7.66
(c) Provisions	-	-
(d) Current Tax Liabilities (Net)	-	-
	<u>12.34</u>	<u>12.67</u>
Total Equity and Liabilities	<u>70.38</u>	<u>15.08</u>

Summary of Significant Accounting Policies

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors

Raymed Labs Limited



Prashant Bajaj

Director & Chairman

DIN- 06634046

Place: Mumbai

Dated: 27th January, 2025



RAYMED LABS LIMITED

STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE PERIOD ENDED DECEMBER 31, 2024

(INR in Lakhs)

Particulars	For The qtr ended December 31, 2024	For The qtr ended September 30, 2024	For The qtr ended December 31, 2023	For the nine month ended December 31, 2024	For the nine month ended December 31, 2023	For the Year ended March 31, 2024
i Revenue						
Revenue from Operations	-	-	-	-	-	-
Other Income	0.86	-	-	0.86	-	-
Total Income	0.86	-	-	0.86	-	-
ii Expenses						
Purchases of Stock in Trade	-	-	-	-	-	-
Change in Inventories of Finished Goods/Work-in-progress/ Stock in Trade	-	-	-	-	-	-
Employee Benefits Expenses	0.40	0.80	0.90	2.10	2.70	3.60
Finance Costs	0.00	0.00	-	0.00	-	-
Depreciation and Amortization Expenses	0.15	0.11	0.09	0.44	0.27	0.48
Other Expenses	25.22	0.74	0.96	26.65	2.26	6.09
Total Expenses	25.77	1.66	1.95	29.20	5.23	10.16
III Profit before tax (I- II)	(24.91)	(1.66)	(1.95)	(28.33)	(5.23)	(10.16)
IV Less: Tax Expense:						
Current Tax	-	-	-	-	-	-
MAT Credit Entitlement	-	-	-	-	-	-
Deferred Tax	-	-	-	-	-	-
Total Tax Expense	-	-	-	-	-	-
V Profit for the Year (III-IV)	(24.91)	(1.66)	(1.95)	(28.33)	(5.23)	(10.16)
VI Other Comprehensive Income						
<u>Items that will not be reclassified to profit or loss</u>						
Re-measurement gains/ (losses) on defined benefit obligations	-	-	-	-	-	-
Tax Effect on above	-	-	-	-	-	-
Other Comprehensive Income for the year, net of tax	-	-	-	-	-	-
VII Total Comprehensive Income for the year (V+VI) (Comprising Profit and Other Comprehensive Income for the year)	(24.91)	(1.66)	(1.95)	(28.33)	(5.23)	(10.16)
VIII Earnings Per Equity Share (Face Value INR 10 Per Share):						
Basic and Diluted (INR)	(0.58)	(0.04)	(0.05)	(0.66)	(0.12)	(0.24)

Summary of Significant Accounting Policies

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors
Raymed Labs Limited


Prashant Bajaj
Director & Chairman
DIN- 06834046
Place: Mumbai
Dated: 27th January, 2025



RAYMED LABS LIMITED
Unaudited Cash Flow Statement for the period ended 31.12.2024

Particulars	For the Year ended Dec 31, 2024	For the Year ended March 31, 2024
A. Cash Flow from Operating Activities		
Net Profit Before Tax	(28.33)	(10.16)
Adjustments:		
Depreciation and Amortization of Property, Plant and Equipment	0.44	0.48
Loss on Sale of property, plant and equipment (net)	-	-
Other Non Cash Items	-	3.84
Fees on Guarantee given on behalf of the Subsidiary Company	-	-
Finance Costs (Including Fair Value Change in Financial Instruments)	0.00	-
Operating cash flows before working capital changes	(27.89)	(5.85)
<u>Adjustments for Changes in Working Capital</u>		
Decrease/ (Increase) in Inventories	-	-
Decrease/ (Increase) in Trade receivables	-	-
Decrease/ (Increase) in Current Loans	-	-
Decrease/ (Increase) in Non-Current Financial Assets - Others	-	-
Decrease/ (Increase) in Other Current Financial Assets	-	-
Decrease/ (Increase) in Other Current Assets	-	-
Increase/ (Decrease) in Trade Payables	-	(0.22)
Increase/ (Decrease) in Current Financial Liabilities - Other	-	-
Increase/ (Decrease) in Other Current Liabilities	(0.33)	-
Increase/ (Decrease) in Non-Current Provisions	-	-
Increase/ (Decrease) in Current Provisions	-	-
Cash generated from operations	(28.22)	(6.07)
Income taxes paid	-	-
Net cash flow from operating activities	(28.22)	(6.07)
Less : Finance cost paid	(0.00)	-
Net cash flow(Used in) from operating activities (A)	(28.22)	(6.07)
B. Cash Flow from Investing Activities		
Purchase or construction of property, plant and equipment (including capital work-in-progress and capital advances)	-	-
Proceeds from/ (Investment in) fixed deposits (net)	-	-
Proceeds from/ (Investment in) Other Bank Balances	-	-
Proceeds from sale of property, plant and equipment	-	-
Purchase or construction of Investment Properties	-	-
Loan taken / (Repayment) of Loan	83.96	6.07
Interest Received	-	-
Dividend Received	-	-
Net cash flow from/ (used in) investing activities (B)	83.96	6.07
C. Cash Flow from Financing Activities		
Increase/(Decrease) Non-Current Financial Liabilities - Borrowings	-	-
Increase/(Decrease)Bank Overdraft	-	-
Proceeds from public issue of shares	-	-
Proceeds from securities premium (net of QIP expenses)	-	-
Net cash flow from financing activities ©	-	-
Net cash Increase/(decrease) in cash and cash equivalents (A+B+C)	55.73	0.00
Cash and cash equivalents at the beginning of the year (Refer Note 9)	0.05	0.05
Cash and cash equivalents at the end of the year (Refer Note 9)	55.79	0.05
Net cash Increase/(decrease) in cash and cash equivalent	55.73	-

The notes referred to above are an integral part of the financial statements.
As per our report of even date

For and on behalf of the Board of Directors
Raymed Labs Limited


Prashant Bajaj
Director & Chairman
DIN- 06634046
Place: Mumbai
Dated: 27th January, 2025



Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Raymed Labs Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Raymed Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone Financial Results of **Raymed Labs Limited** ("the Company") for the quarter ended 31st December 2024 ("the statement"). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations)
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K T P S & Co.

Chartered Accountants

Firm's Registration No. 134942W



CA Anurag Khandelia

Partner

Mem. No. 172909

UDIN: 25172909BMIGDN9220

Place: Mumbai

Date: 27/01/2025